

Chapter 14

REFERENCES

1. Smith HW. *Lectures on the Kidney*. Lawrence, KS: University Extension Division, University of Kansas; 1943.
2. Preuss HG. Basics of renal anatomy and physiology. *Clin Lab Med*. 1993;13:1-11.
3. Brezis M, Epstein FH. Cellular mechanisms of acute ischemic injury in the kidney. *Annu Rev Med*. 1993;44:27-37.
4. Leonhardt K, Landes R, McCauley R. Anatomy and physiology of intrarenal oxygen tension: preliminary study of the effect of anesthetics. *Anesthesiology*. 1965;26:648-658.
5. Brezis M, Rosen S. Hypoxia of the renal medulla—its implications for disease. *N Engl J Med*. 1995;332:647-655.
6. Alpert RA, Roizen MF, Hamilton WK, et al. Intraoperative urinary output does not predict postoperative renal function in patients undergoing abdominal aortic revascularization. *Surgery*. 1984;95:707-711.
7. Conlon PJ, Stafford-Smith M, White WD, et al. Acute renal failure following cardiac surgery. *Nephrol Dial Transplant*. 1999;14:1158-1162.
8. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis*. 2003;41:1-12.
9. Levin A. Cystatin C, serum creatinine, and estimates of kidney function: searching for better measures of kidney function and cardiovascular risk. *Ann Intern Med*. 2005;142:586-588.
10. Grubb A, Björk J, Lindström V, Sterner G, Bondesson P, Nyman U. A cystatin C-based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft-Gault formula. *Scand J Clin Lab Invest*. 2005;65:153-162.
11. Sladen RN, Endo E, Harrison T. Two-hour versus 22-hour creatinine clearance in critically ill patients. *Anesthesiology*. 1987;67:1013-1016.
12. Bloor GK, Welsh KR, Goodall S, et al. Comparison of predicted with measured creatinine clearance in cardiac surgical patients. *J Cardiothorac Vasc Anesth*. 1996;10:899-902.
13. Gowans EM, Fraser CG. Biological variation of serum and urine creatinine and creatinine clearance: ramifications for interpretation of results and patient care. *Ann Clin Biochem*. 1988;25:259-263.
14. Morgan DB, Dillon S, Payne RB. The assessment of glomerular function: creatinine clearance or plasma creatinine? *Postgrad Med J*. 1978;54:302-310.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron*. 1976;16:31-41.
16. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med*. 1999;130:461-470.
17. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care*. 2004;8:R204-R212.
18. Ferguson TB Jr, Dziuban SW Jr, Edwards FH, et al. The STS National Database: current changes and challenges for the new millennium. Committee to Establish a National Database in Cardiothoracic Surgery, The Society of Thoracic Surgeons. *Ann Thorac Surg*. 2000;69:680-691.
19. Barrett BJ, Parfrey PS. Prevention of nephrotoxicity induced by radiocontrast agents. *N Engl J Med*. 1994;331:1449-1450.
20. Greenberg A, ed. *Primer on Kidney Diseases*. 4th ed. Philadelphia, PA: Elsevier Saunders; 2005.
21. Smith MS. Antifibrinolytic agents make alpha1- and beta2-microglobulinuria poor markers of postcardiac surgery renal dysfunction. *Anesthesiology*. 1999;90:928-929.
22. Solhaug MJ, Bolger PM, Jose PA. The developing kidney and environmental toxins. *Pediatrics*. 2004;113:1084-1091.
23. Fernandez F, de Miguel MD, Barrio V, et al. Beta-2-microglobulin as an index of renal function after cardiopulmonary bypass surgery in children. *Child Nephrol Urol*. 1988;9:326-330.
24. Lindeman RD. Overview: renal physiology and pathophysiology of aging. *Am J Kidney Dis*. 1990;16:275-282.
25. Lindeman RD. Assessment of renal function in the old. Special considerations. *Clin Lab Med*. 1993;13:269-277.
26. Fliser D, Franek E, Joest M, et al. Renal function in the elderly: impact of hypertension and cardiac function. *Kidney Int*. 1997;51:1196-1204.
27. Anderson S, Brenner BM. Effects of aging on the renal glomerulus. *Am J Med*. 1986;80:435-442.
28. Mühlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. *Gerontology*. 1999;45:243-253.
29. Anderson RJ, Chung HM, Kluge R, et al. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. *Ann Intern Med*. 1985;102:164-168.

30. Verbalis JG. Hyponatremia: epidemiology, pathophysiology, and therapy. *Curr Opin Nephrol Hypertens*. 1993;2:636-652.
31. Arieff AI. Hyponatremia, convulsions, respiratory arrest, and permanent brain damage after elective surgery in healthy women. *N Engl J Med*. 1986;314:1529-1535.
32. Arieff AI, Ayus JC, Fraser CL. Hyponatremia and death or permanent brain damage in healthy children. *BMJ*. 1992;304:1218-1222.
33. Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatremic encephalopathy in menstruant women. *Ann Intern Med*. 1992;117:891-897.
34. Sterns RH, Cappuccio JD, Silver SM, et al. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. *J Am Soc Nephrol*. 1994;4:1522-1530.
35. Hodgkin JE, Soeprono FF, Chan DM. Incidence of metabolic alkalemia in hospitalized patients. *Crit Care Med*. 1980;8:725-728.
36. Rudolph R, Boyd CR. Massive transfusion: complications and their management. *South Med J*. 1990;83:1065-1070.
37. Isaacson SR. Hypocalcemia in surgery for carcinoma of the pharynx and larynx. *Otolaryngol Clin North Am*. 1980;13:181-191.
38. Suki WN, Yium JJ, Von Minden M, et al. Acute treatment of hypercalcemia with furosemide. *N Engl J Med*. 1970;283:836-840.
39. Mordes JP, Wacker WE. Excess magnesium. *Pharmacol Rev*. 1977;29:273-300.
40. Sutton RA, Domrongkitchaiporn S. Abnormal renal magnesium handling. *Miner Electrolyte Metab*. 1993;19:232-240.
41. Jones JE, Shane SR, Jacobs WH, et al. Magnesium balance studies in chronic alcoholism. *Ann N Y Acad Sci*. 1969;162:934-946.
42. Dickerson RN, Brown RO. Hypomagnesemia in hospitalized patients receiving nutritional support. *Heart Lung*. 1985;14:561-569.
43. Booth CC, Babouris N, Hanna S, et al. Incidence of hypomagnesemia in intestinal malabsorption. *Br Med J*. 1963;5350:141-144.
44. Schuck P, Gammelin G, Resch KL. Magnesium and phosphorus. *Lancet*. 1998;352:1474-1475; author reply 1475-1476.
45. Weisinger JR, Bellor'n-Font E. Magnesium and phosphorus. *Lancet*. 1998;352:391-396.
46. Gray RW, Wilz DR, Caldas AE, et al. The importance of phosphate in regulating plasma 1,25-(OH)₂-vitamin D levels in humans: studies in healthy subjects in calcium-stone formers and in patients with primary hyperparathyroidism. *J Clin Endocrinol Metab*. 1977;45:299-306.
47. Knochel JP. The pathophysiology and clinical characteristics of severe hypophosphatemia. *Arch Intern Med*. 1977;137:203-220.
48. Larson EB, Roach RC, Schoene RB, et al. Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. *JAMA*. 1982;248:328-332.
49. White DP, Zwillich CW, Pickett CK, et al. Central sleep apnea. Improvement with acetazolamide therapy. *Arch Intern Med*. 1982;142:1816-1819.
50. Better OS, Rubinstein I, Winaver JM, et al. Mannitol therapy revisited (1940-1997). *Kidney Int*. 1997;52:886-894.
51. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. *N Engl J Med*. 1994;331:1416-1420.
52. Conger JD. Interventions in clinical acute renal failure: what are the data? *Am J Kidney Dis*. 1995;26:565-576.
53. Toung TJ, Hurn PD, Traystman RJ, et al. Global brain water increases after experimental focal cerebral ischemia: effect of hypertonic saline. *Crit Care Med*. 2002;30:644-649.
54. Borges HF, Hocks J, Kjellstrand CM. Mannitol intoxication in patients with renal failure. *Arch Intern Med*. 1982;142:63-66.
55. Bailly C. Transducing pathways involved in the control of NaCl reabsorption in the thick ascending limb of Henle's loop. *Kidney Int Suppl*. 1998;65:S29-S35.
56. Isenring P, Forbush B. Ion transport and ligand binding by the Na-K-Cl cotransporter, structure-function studies. *Comp Biochem Physiol A Mol Integr Physiol*. 2001;130:487-497.
57. Gallagher KL, Jones JK. Furosemide-induced ototoxicity. *Ann Intern Med*. 1979;91:744-745.
58. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med*. 1999;341:709-717.
59. Brater DC. Diuretic therapy. *N Engl J Med*. 1998;339:387-395.
60. Knauf H, Möhrke W, Mutschler E. Delayed elimination of triamterene and its active metabolite in chronic renal failure. *Eur J Clin Pharmacol*. 1983;24:453-456.
61. Mutschler E, Gilfrich HJ, Knauf H, et al. Pharmacokinetics of triamterene. *Clin Exp Hypertens A*. 1983;5:249-269.
62. de Gasparo M, Whitebread SE, Preiswerk G, et al. Antialdosterones: incidence and prevention of sexual side effects. *J Steroid Biochem*. 1989;32:223-227.
63. Jose PA, Felder RA. What we can learn from the selective manipulation of dopaminergic receptors about the pathogenesis and treatment of hypertension? *Curr Opin Nephrol Hypertens*. 1996;5:447-451.
64. Bellomo R, Cole L, Ronco C. Hemodynamic support and the role of dopamine. *Kidney Int Suppl*. 1998;66:S71-S74.
65. Marik PE. Low-dose dopamine: a systematic review. *Intensive Care Med*. 2002;28:877-883.
66. Kellum JA, M Decker J. Use of dopamine in acute renal failure: a meta-analysis. *Crit Care Med*. 2001;29:1526-1531.
67. Prins I, Plötz FB, Uiterwaal CS, van Vught HJ. Low-dose dopamine in neonatal and pediatric intensive care: a systematic review. *Intensive Care Med*. 2001;27:206-210.
68. Holmes CL, Walley KR. Bad medicine: low-dose dopamine in the ICU. *Chest*. 2003;123:1266-1275.
69. Argalious M, Motta P, Khandwala F, et al. "Renal dose" dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery. *Crit Care Med*. 2005;33:1327-1332.
70. Denton MD, Chertow GM, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. *Kidney Int*. 1996;50:4-14.
71. Hou SH, Bushinsky DA, Wish JB, et al. Hospital-acquired renal insufficiency: a prospective study. *Am J Med*. 1983;74:243-248.
72. Anderson JD, Smith RB. Renal failure associated with vesicoureteral reflux. *Urology*. 1977;10:539-543.
73. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. *Am J Med*. 1999;106:13S-24S.
74. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. *Am J Kidney Dis*. 1996;28:S56-S62.
75. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. *Am J Epidemiol*. 2000;151:488-496.

76. Zhao SZ, Reynolds MW, Lejkowith J, et al. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. *Clin Ther.* 2001;23:1478-1491.
77. Knight EL, Glynn RJ, McIntyre KM, et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). *Am Heart J.* 1999;138:849-855.
78. Schoolwerth AC, Sica DA, Ballermann BJ, et al. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. *Circulation.* 2001;104:1985-1991.
79. Adhiyaman V, Asghar M, Oke A, et al. Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. *J R Soc Med.* 2001;94:512-514.
80. Kincaid EH, Ashburn DA, Hoyle JR, et al. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery? *Ann Thorac Surg.* 2005;80:1388-1393.
81. Michel DM, Kelly CJ. Acute interstitial nephritis. *J Am Soc Nephrol.* 1998;9:506-515.
82. Rastegar A, Kashgarian M. The clinical spectrum of tubulointerstitial nephritis. *Kidney Int.* 1998;54:313-327.
83. Kelly CJ. T cell regulation of autoimmune interstitial nephritis. *J Am Soc Nephrol.* 1990;1:140-149.
84. Eddy AA, McCulloch L, Liu E, et al. A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome. *Am J Pathol.* 1991;138:1111-1123.
85. Neilson EG. Pathogenesis and therapy of interstitial nephritis. *Kidney Int.* 1989;35:1257-1270.
86. Neilson EG, Sun MJ, Kelly CJ, et al. Molecular characterization of a major nephritogenic domain in the autoantigen of anti-tubular basement membrane disease. *Proc Natl Acad Sci U S A.* 1991;88:2006-2010.
87. Wilson CB. Nephritogenic tubulointerstitial antigens. *Kidney Int.* 1991;39:501-517.
88. Linton AL, Clark WF, Driedger AA, et al. Acute interstitial nephritis due to drugs: Review of the literature with a report of nine cases. *Ann Intern Med.* 1980;93:735-741.
89. Rossert J. Drug-induced acute interstitial nephritis. *Kidney Int.* 2001;60:804-817.
90. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. *N Engl J Med.* 1984;310:563-572.
91. Kleinknecht D. Interstitial nephritis, the nephrotic syndrome, and chronic renal failure secondary to nonsteroidal anti-inflammatory drugs. *Semin Nephrol.* 1995;15:228-235.
92. Lien YH, Hansen R, Kern WF, et al. Ciprofloxacin-induced granulomatous interstitial nephritis and localized elastolysis. *Am J Kidney Dis.* 1993;22:598-602.
93. Cryst C, Hammar SP. Acute granulomatous interstitial nephritis due to co-trimoxazole. *Am J Nephrol.* 1988;8:483-488.
94. Webb DE, Austin HA 3rd, Belldegrin A, et al. Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. *Clin Nephrol.* 1988;30:141-145.
95. Ault BH, Stapleton FB, Gaber L, et al. Acute renal failure during therapy with recombinant human gamma interferon. *N Engl J Med.* 1988;319:1397-1400.
96. Ruffing KA, Hoppes P, Blend D, et al. Eosinophils in urine revisited. *Clin Nephrol.* 1994;41:163-166.
97. Nolan CR 3rd, Anger MS, Kelleher SP. Eosinophiluria—a new method of detection and definition of the clinical spectrum. *N Engl J Med.* 1986;315:1516-1519.
98. Galpin JE, Shinaberger JH, Stanley TM, et al. Acute interstitial nephritis due to methicillin. *Am J Med.* 1978;65:756-765.
99. Pusey CD, Saltissi D, Bloodworth L, et al. Drug associated acute interstitial nephritis: clinical and pathological features and the response to high dose steroid therapy. *Q J Med.* 1983;52:194-211.
100. Huang JJ, Sung JM, Chen KW, et al. Acute bacterial nephritis: a clinicoradiologic correlation based on computed tomography. *Am J Med.* 1992;93:289-298.
101. Wise GJ, Silver DA. Fungal infections of the genitourinary system. *J Urol.* 1993;149:1377-1388.
102. Bhattacharya S, Bryk D, Wise GJ. Clinicopathological conference: renal pelvic filling defect in a diabetic woman. *J Urol.* 1982;127:751-753.
103. Wise GJ, Kozinn PJ, Goldberg P. Amphotericin B as a urologic irrigant in the management of noninvasive candiduria. *J Urol.* 1982;128:82-84.
104. Ramsay AG, Olesnick L, Pirani CL. Acute tubulo-interstitial nephritis from candida albicans with oliguric renal failure. *Clin Nephrol.* 1985;24:310-314.
105. Levy E, Bia MJ. Isolated renal mucormycosis: case report and review. *J Am Soc Nephrol.* 1995;5:2014-2019.
106. Myerowitz RL, Stalder H, Oxman MN, et al. Fatal disseminated adenovirus infection in a renal transplant recipient. *Am J Med.* 1975;59:591-598.
107. Erdoğan O, Bülbül M, Demircin G, Oner A, Memiş L. Acute necrotizing tubulointerstitial nephritis due to systemic adenoviral infection. *Pediatr Nephrol.* 2001;16:265-268.
108. Rosen S, Harmon W, Krensky AM, et al. Tubulo-interstitial nephritis associated with polyomavirus (BK type) infection. *N Engl J Med.* 1983;308:1192-1196.
109. Nasr SH, Kosica J, Markowitz GS, et al. Granulomatous interstitial nephritis. *Am J Kidney Dis.* 2003;41:714-719.
110. Walker JV, Baran D, Yakub N, et al. Histoplasmosis with hypercalcemia, renal failure, and papillary necrosis. Confusion with sarcoidosis. *JAMA.* 1977;237:1350-1352.
111. Frazão JM, Elangovan L, Felsenfeld AJ, Stanley TM, Cohen AH. Epstein-Barr-virus-induced interstitial nephritis in an HIV-positive patient with progressive renal failure. *Nephrol Dial Transplant.* 1998;13:1849-1852.
112. Mayer HB, Wanke CA, Williams M, et al. Epstein-Barr virus-induced infectious mononucleosis complicated by acute renal failure: case report and review. *Clin Infect Dis.* 1996;22:1009-1018.
113. Kramer L, Hörl WH. Hepatorenal syndrome. *Semin Nephrol.* 2002;22:290-301.
114. Ginès P, Arroyo V. Hepatorenal syndrome. *J Am Soc Nephrol.* 1999;10:1833-1839.
115. Gonwa TA, Klintmalm GB, Levy M, et al. Impact of pretransplant renal function on survival after liver transplantation. *Transplantation.* 1995;59:361-365.
116. Guevara M, Ginès P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. *Hepatology.* 1998;28:416-422.

117. Uriz J, Ginès P, Cárdenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. *J Hepatol.* 2000;33:43-48.
118. Mulkey JP, Louis H, Donckier V, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. *Acta Gastroenterol Belg.* 2001;64:15-19.
119. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. *Hepatology.* 1999;29:1690-1697.
120. Holt S, Goodier D, Marley R, et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. *Lancet.* 1999;353:294-295.
121. Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. *Gut.* 2000;47:288-295.
122. Arroyo V, Ginès P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. *Hepatology.* 1996;23:164-176.
123. Porter GA. Contrast-associated nephropathy: presentation, pathophysiology and management. *Miner Electrolyte Metab.* 1994;20:232-243.
124. Kahn JK, Rutherford BD, McConahay DR, et al. High-dose contrast agent administration during complex coronary angioplasty. *Am Heart J.* 1990;120:533-536.
125. Gussenhoven MJ, Ravensbergen J, van Bockel JH, et al. Renal dysfunction after angiography; a risk factor analysis in patients with peripheral vascular disease. *J Cardiovasc Surg (Torino).* 1991;32:81-86.
126. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. *JAMA.* 2004;291:2328-2334.
127. Provenchère S, Plantefève G, Hufnagel G, et al. Renal dysfunction after cardiac surgery with normothermic cardiopulmonary bypass: incidence, risk factors, and effect on clinical outcome. *Anesth Analg.* 2003;96:1258-1264.
128. Myers BD, Newton L. Cyclosporine-induced chronic nephropathy: an obliterative microvascular renal injury. *J Am Soc Nephrol.* 1991;2:S45-52.
129. Myers BD, Sibley R, Newton L, et al. The long-term course of cyclosporine-associated chronic nephropathy. *Kidney Int.* 1988;33:590-600.
130. Lopau K, Kleinert D, Erler J, et al. Tacrolimus in acute renal failure: does L-arginine-infusion prevent changes in renal hemodynamics? *Transpl Int.* 2000;13:436-442.
131. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. *Curr Opin Hematol.* 2001;8:286-293.
132. Busca A, Uderzo C. BMT: Bone marrow transplant associated thrombotic microangiopathy. *Hematol.* 2000;5:53-67.
133. Gharpure VS, Devine SM, Holland HK, et al. Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation. *Bone Marrow Transplant.* 1995;16:715-716.
134. Kamel KS, Ethier JH, Quaggin S, et al. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine. *J Am Soc Nephrol.* 1992;2:1279-1284.
135. Novis BK, Roizen MF, Aronson S, et al. Association of preoperative risk factors with postoperative acute renal failure. *Anesth Analg.* 1994;78:143-149.
136. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. *JAMA.* 1996;275:1489-1494.
137. Chertow GM, Levy EM, Hammermeister KE, et al. Independent association between acute renal failure and mortality following cardiac surgery. *Am J Med.* 1998;104:343-348.
138. Urschel JD, Antkowiak JG, Takita H. Acute renal failure following pulmonary surgery. *J Cardiovasc Surg (Torino).* 1994;35:215-218.
139. Stafford-Smith M. Perioperative renal dysfunction: implications and strategies for protection. In: Newman MF, ed. *Perioperative Organ Protection.* Baltimore, MD: Lippincott Williams & Wilkins; 2003:89-124.
140. Rabb H, Wang Z, Nemoto T, et al. Acute renal failure leads to dysregulation of lung salt and water channels. *Kidney Int.* 2003;63:600-606.
141. Kelly KJ. Distant effects of experimental renal ischemia/reperfusion injury. *J Am Soc Nephrol.* 2003;14:1549-1558.
142. Conlon PJ, Lynn K, Winn MP, et al. Spectrum of disease in familial focal and segmental glomerulosclerosis. *Kidney Int.* 1999;56:1863-1871.
143. Zanardo G, Michielon P, Paccagnella A, et al. Acute renal failure in the patient undergoing cardiac operation. Prevalence, mortality rate, and main risk factors. *J Thorac Cardiovasc Surg.* 1994;107:1489-1495.
144. Abel RM, Buckley MJ, Austen WG, et al. Etiology, incidence, and prognosis of renal failure following cardiac operations. Results of a prospective analysis of 500 consecutive patients. *J Thorac Cardiovasc Surg.* 1976;71:323-333.
145. Andersson LG, Ekroth R, Bratteby LE, et al. Acute renal failure after coronary surgery—a study of incidence and risk factors in 2009 consecutive patients. *Thorac Cardiovasc Surg.* 1993;41:237-241.
146. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. *Ann Intern Med.* 1998;128:194-203.
147. Corwin HL, Sprague SM, DeLaria GA, et al. Acute renal failure associated with cardiac operations. A case-control study. *J Thorac Cardiovasc Surg.* 1989;98:1107-1112.
148. Chertow GM, Lazarus JM, Christiansen CL, et al. Preoperative renal risk stratification. *Circulation.* 1997;95:878-884.
149. Ostermann ME, Taube D, Morgan CJ, et al. Acute renal failure following cardiopulmonary bypass: a changing picture. *Intensive Care Med.* 2000;26:565-571.
150. Swaminathan M, Phillips-Bute BG, Conlon PJ, et al. The association of lowest hematocrit during cardiopulmonary bypass with acute renal injury after coronary bypass surgery. *Ann Thorac Surg.* 2003;76:784-791.
151. Hilberman M, Myers BD, Carrie BJ, et al. Acute renal failure following cardiac surgery. *J Thorac Cardiovasc Surg.* 1979;77:880-888.
152. Llopart T, Lombardi R, Forselledo M, et al. Acute renal failure in open heart surgery. *Ren Fail.* 1997;19:319-323.
153. Chew ST, Newman MF, White WD, et al. Preliminary report on the association of apolipoprotein E polymorphisms, with

- postoperative peak serum creatinine concentrations in cardiac surgical patients. *Anesthesiology*. 2000;93:325-331.
154. Gaudino M, Di Castelnuovo A, Zamparelli R, et al. Genetic control of postoperative systemic inflammatory reaction and pulmonary and renal complications after coronary artery surgery. *J Thorac Cardiovasc Surg*. 2003;126:1107-1112.
 155. Mangos GJ, Brown MA, Chan WY, et al. Acute renal failure following cardiac surgery: incidence, outcomes and risk factors. *Aust N Z J Med*. 1995;25:284-289.
 156. Stafford-Smith M, Phillips-Bute B, Reddan DN, et al. The association of postoperative peak and fractional change in serum creatinine with mortality after coronary bypass surgery. *Anesthesiology*. 2000;93:A240.
 157. Rao V, Weisel RD, Buth KJ, et al. Coronary artery bypass grafting in patients with non-dialysis-dependent renal insufficiency. *Circulation*. 1997;96:II-38-43.
 158. Anderson RJ, O'Brien M, MaWhinney S, et al. Mild renal failure is associated with adverse outcome after cardiac valve surgery. *Am J Kidney Dis*. 2000;35:1127-1134.
 159. Anderson RJ, O'Brien M, MaWhinney S, et al. Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery. VA Cooperative Study #5. *Kidney Int*. 1999;55:1057-1062.